ASX
Paradigm Biopharmaceuticals Limited
PAR:ASX•Healthcare
Sensitive ASX Announcement
PARs Osteoarthritis Phase 2 Receives Ethics Approval
Published: 19/09/17, 08:34am (AEST)•4 pages